Tetra Bio-Pharma today announced a new CBD supply agreement with Alberta-based True North Cannabis.
True North will supply Tetra with high-quality, competitively priced CBD.
The new agreement helps cement Tetra’s increasingly strong position as a leader in developing, and now commercializing, topical pain-relief products derived from cannabinoids.
A recent agreement with Genacol Canada aims to get Tetra’s oral capsule and a topical cream into the $2.5-billion market for joint-pain-and inflammation products.
Under the terms of that agreement, Tetra Bio-Pharma will use its formulation and regulatory expertise, and its clinical-trial data from its topical cannabinoid and cannabis-oil capsules, to create innovative products for Genacol.
“Price to consumers is a critical aspect for the viability of a commercial product in the self-care health market,” said Tetra’s interim CEO and chief scientific officer Guy Chamberland.
“True North Cannabis has built a state-of-the-art facility in Alberta, which will provide the highest quality CBD for Tetra, at a competitive price, to develop innovative products in partnership with Genacol,” Dr. Chamberland said.
True North CEO Shayne Hamilton said the deal leverages the size and scale of the industrial hemp crop in Canada.
The company’s agreement with Tetra Bio-Pharma gives it a “unique opportunity to market (its) product,” he said.
Dr. Chamberland recently said the Genacol agreement will command a great deal of exposure for Tetra’s products.
He estimates that the products “will generate several millions of dollars in sales for Genacol in Canada.”
The companies plan to launch the products in 2019, when they will be marketed throughout Genacol’s network in Canada.
The Genacol trademark is registered in 81 countries worldwide and the company’s sales network is active in over 40 countries.
The development and marketing company’s success is based on its collagen ingredient that is manufactured using a proprietary process called AminoLock® Sequential Technology.
Tetra has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements.
The company provides rigorous scientific validation and safety data for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Copyright Notice ©CannabisFindings.com. 2018. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to CannabisFindings.com with appropriate and specific direction to the original content.